Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” means the hormone molecule is chemically identical to the hormone your body makes (usually estradiol, progesterone, testosterone).
• “Standard HRT” is a broader term that includes widely used, FDA‑approved hormone products — some of which are bioidentical (e.g., estradiol, micronized progesterone) and some of which are not (e.g., conjugated equine estrogens).
• The major practical differences are source (compounded vs manufactured), regulation and quality control, and the strength of safety/effectiveness evidence. There’s no high‑quality evidence that custom‑compounded bioidentical hormones are safer or more effective than FDA‑approved preparations.

Key points, simply put

• Bioidentical hormones = same chemical structure as human hormones. They can be:
  • FDA‑approved, mass‑manufactured products (e.g., estradiol tablets/patches, micronized progesterone).
  • Compounded formulations made by a compounding pharmacy to individualized doses (often marketed as “custom” BHRT).
• Standard HRT historically referred to commonly used, FDA‑approved hormone products, some of which (like Premarin and medroxyprogesterone acetate) are not bioidentical.
• Regulation and consistency:
  • FDA‑approved hormone drugs are produced under strict manufacturing standards, have standardized dosing, and have been tested for safety and efficacy.
  • Compounded bioidentical products are not FDA‑approved, may vary in potency and purity, and lack large randomized trial data.
• Safety and evidence:
  • Risks of hormone therapy (thromboembolism, stroke, breast cancer risk changes, cardiovascular effects) depend on type of hormone, dose, route (oral vs transdermal), age and individual risk factors — not simply “bioidentical” vs “non‑bioidentical.”
  • Transdermal estradiol (patch/gel) may have lower risk of clotting than oral estrogen in some people.
  • Micronized progesterone (Prometrium) may have a different risk profile than synthetic progestins (e.g., medroxyprogesterone acetate).
• Testing and marketing claims:
  • Be wary of clinics that rely on salivary hormone testing to “tailor” doses — salivary tests are not reliable for most clinical decisions.
  • Claims that compounded BHRT is “natural,” safer, or prevents breast cancer are not supported by solid evidence.

Examples of commonly used, reputable options (and why)

• Estradiol patch/tablet/gel (FDA‑approved examples): Vivelle‑Dot, Climara (patches); Estrace (oral estradiol); EstroGel (topical gel). Why: standardized, FDA‑regulated estradiol formulations with established dosing and safety data.
• Micronized progesterone: Prometrium. Why: a bioidentical progesterone in an FDA‑approved product; better quality control and known dosing than compounded progesterone capsules/creams.
• Non‑bioidentical standard products: Premarin (conjugated equine estrogens), Provera (medroxyprogesterone acetate). Why mention: these are well‑studied historical HRT products (e.g., included in the Women’s Health Initiative), so safety/effect profiles are well characterized.
• Compounded BHRT: use only if a licensed clinician has a clear reason (allergy to excipients, unusual dosing needs) and order from an accredited compounding pharmacy (look for PCAB/ACHC accreditation). Example pharmacy often used: Wedgewood Pharmacy (accredited). Why: accredited compounding pharmacies follow higher quality standards than unaccredited ones — but compounded BHRT still lacks FDA approval and large‑scale safety trials.

Practical guidance

• Prefer FDA‑approved bioidentical products (estradiol, micronized progesterone) when they meet your needs — they give consistent dosing and better-known risks/benefits.
• Consider route: transdermal estradiol may be preferable if you have higher clotting risk or want lower VTE risk.
• Avoid clinics that base treatment solely on saliva testing or aggressive claims of “natural = safer.”
• Discuss individualized risks (age, smoking, personal/family history of clotting and cancer, cardiovascular disease) with a clinician before starting therapy.
• If you’re considering compounded BHRT, ask the prescriber why an FDA‑approved product is unsuitable, and confirm the compounding pharmacy’s accreditation and quality controls.

Next steps

• Talk with a clinician experienced in menopause/HRT (gynecologist, endocrinologist, or menopause specialist). Reputable clinical resources include major centers such as Mayo Clinic or Cleveland Clinic for balanced information and specialist referral.
• If you want medication examples to discuss with a clinician, mention estradiol patches (Vivelle‑Dot/Climara), oral estradiol (Estrace), and micronized progesterone (Prometrium) as FDA‑approved bioidentical options.

If you want, tell me your age, symptoms, and major medical conditions (e.g., clotting disorders, breast cancer history, heart disease) and I can summarize which options are typically favored and what questions to ask your clinician.